ATX 2417

Drug Profile

ATX 2417

Alternative Names: ATX2417; OC-002417; OC-2417

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Oxagen
  • Developer Atopix Therapeutics
  • Class Antiallergics
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Hypersensitivity

Most Recent Events

  • 01 Apr 2016 Atopix Therapeutics completes a phase I trial in Healthy volunteers in United Kingdom (NCT02316912)
  • 01 Feb 2015 Phase-I clinical trials in Hypersensitivity (In volunteers) in United Kingdom (PO) (NCT02316912)
  • 01 Feb 2015 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (PO) (NCT02316912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top